Shots:

• Merck to receive ~$1.2B to supply ~1.7M courses of molnupiravir to the US government- if its receives EUA or approval from the US FDA and expects to have 10M+ courses of therapy available by the end of 2021
• The therapy is currently being evaluated in a P-III MOVe-OUT study in non-hospitalized patients with COVID-19. Merck also plans to file for EUA or approval outside the US
• Merck is collaborated with generic manufacturers to accelerate the availability of the therapy in 104 LMICs- following the approvals or EUA by local regulatory agencies & plans to initiate a clinical program of molnupiravir for post-exposure prophylaxis in H2'21

  Ref: Business Wire | Image: Molnupiravir